Observed Signal · Sep 8, 2026 · Market Signal · Source: Beiersdorf · Impact: 3/5
Epigenetics & Skin Longevity: 17 Years of Beiersdorf Research
Beiersdorf is stepping up its epigenetics research. New studies prove the high efficacy of epigenetic ingredients in skin care products.
Track Beiersdorf Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Connected Companies & Entities
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Beiersdorf Strengthens Derma Business With Eucerin DERMOPURE CLINICAL PROBIOM8
Beiersdorf introduces a new skin care approach for acne-prone skin with Eucerin DERMOPURE CLINICAL PROBIOM8, strengthening its derma business.
SciBase EIS Technology Chosen for NIH Skin Barrier Study
SciBase Holding AB announced that its Nevisense device, utilizing Electrical Impedance Spectroscopy (EIS), has been selected as the primary endpoint in the NIH-led THREAT study, conducted in collaboration with the Swiss Institute of Allergy and Asthma Research (SIAF). The study will expose 80 healthy volunteers to common skin products containing sodium lauryl sulfate (SLS), synthetic bedding and clothing, or natural alternatives, and measure skin barrier function using EIS. The research aims to explore how environmental exposures impact skin barrier health, with implications for dermatology, cosmetics, and skincare product development. The study design was published in the journal Allergy. CEO Pia Renaudin expressed pride in the technology's selection, highlighting its scientific relevance and potential to expand SciBase's role in dermatology research.
Receive all future signals for Beiersdorf & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.
